Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 4, 1997, Pages 368-372

  Ramnath, N ^a   LoRusso, P ^a   Simon, M ^a   Martino, S ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b Westlake Comprehensive Cancer Center   (United States)

Author keywords

Cisplatin; Metastatic breast cancer; WR2721

Indexed keywords

AMIFOSTINE; CISPLATIN;

ADULT; AGED; ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; VOMITING;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BONE NEOPLASMS; BREAST NEOPLASMS; CAUSE OF DEATH; CISPLATIN; COCHLEA; FEMALE; HUMANS; HYPOTENSION; INJECTIONS, INTRAVENOUS; KIDNEY; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; RADIATION-PROTECTIVE AGENTS; REMISSION INDUCTION; SALVAGE THERAPY; THORACIC NEOPLASMS; VOMITING;

EID: 0030753821     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199708000-00009     Document Type: Article

References (25)

1. Yap Hwee-Yong Salem, Philip H, Hortobagyi NG, et al. Phase II study of cisdichlordiammineplatinum in advanced breast cancer. Cancer Treat Rep 1978;3:405-8.
2. Martino S, Samal BA, Singhakowinta A, et al. A Phase II study of CWS-diammine dichloroplatinum II for advanced breast cancer, two dose schedules. J Cancer Res Clin Oncol 1984;108: 354-6.
3. Forastiere A, Hakes B, Thomas B, et al. Cisplatin in the treatment of metastatic breast cancer. A prospective randomized trial of 2 dosage schedules. Am J Clin Oncol (CCT) 1982;5: 243-7.
4. Sledge W, Loeher G, Jr, Patrick J, et al. Cisplatin as first line therapy for metastatic breast cancer. J Clin Oncol 1988;12: 1811-4.
5. Kolaric K, Roth A. Phase II clinical trial of CWS-platinum for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983;11:108-12.
6. Mechl Z, Sopkova B. CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer. Neoplasma 1984;31:431-5.
7. Yuhas JM, Storer JB. Differential chemoprotection of normal and malignant tissues. JNCI 1969;42:331-5.
8. Glover D, Glick HJ, et al. Phase I trials of WR2721 and cisplatinum. Int J Radiat Oncol Biol Phys 1986;10:1781-4.
9. Glover D, Glick HJ, Weiler C, et al. Phase I/II trials of WR2721 and cisplatinum. Int J Radiat Oncol Biol Phys 1986;12:1509-12.
10. Glover D, Glick HJ, Weiler C, et al. WR2721 protects against the hemotologic toxicity of cyclosphophamide. A controlled phase II Trial. J Clin Oncol 1986;4:584-8.
11. Creagan E, Green S, Ahmann D, et al. A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, CIS-platinum with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer. J Clin Oncol 1984;11:1260-5.
12. Kolaric Kristo, Roth Anton, Vukas D, Cervek JI. CAP vs CMFVP combination chemotherapy in untreated metastatic breast cancer. Cancer Chemother Pharmacol 1984;13:142-4.
13. Zamboni A, Marpicati P, Simoncini E, et al. Cyclophosphamide, epirubicin and cisplatin in advanced breast cancer: preliminary results. Anticancer Res 1987;7:813-6.
14. Gandara RD, Perez AE, Wiebe V, et al. CWS-platinum chemoprotection and rescue. Pharmacologic modulation of toxicity. Semin Oncol 1991;1(suppl 3):49-55.
15. McCullogh W, Scheffler BJ, Schein PS. New protective agents for bone marrow in cancer therapy. Cancer Invest 1991;9:279-87.
16. Gandara RD, Wiebe JV, Perez AE, et al. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721 and diethylthiocarbamate. Crit Rev Oncol Hematol 1990;4:353-65.
17. Glick J, Kemp G, Rose P, et al. A randomized trial of cyclophosphamide and cisplatin ± WR2721 in the treatment of advanced epithelial ovarian cancer. Proc ASCO 1992;11:258.
18. Kish J, Ensley J, Al-Saraff M. Evaluation of WR2721 + cisplatin + 5-fluorouracil (5FU) infusion in patients with recurrent advanced head and neck cancer. Proc Third Int Conf Head Neck Cancer 1992;116:79.
19. Mehta M, Schiller JH, Bastin K, et al. Pilot study of WR2721/ CDDP/VLB and sequential TRT/WR2721 in stage III NSCLC: preliminary results. Proc ASCO 1991;10:912.
20. Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 1996;14:1913-21.
21. Planting AST, Vermorken JB, Catimel G, et al. Randomized phase II study of weekly cisplatin with or without amifostine in patients with advanced head and neck cancer. Proc ASCO 1996;15:887.
22. Glover D, Graketsky S, Fox K, et al. Clinical trials of WR2721 and cisplatinum. Int J Radiat Oncol Biol Phys 1989;16:1201-4.
23. Mollman EJ, Glover JD, Hogan M, et al. Cisplatin neuropathy; risk factors, prognosis and protection by WR2721. Cancer 1988;61:2192-5.
24. Citkovic E, Hayes DM, Golbey RB, Krakoff IH. Cisplatin nephrotoxicity: diethyldithiocarbamate, WR2721, or just water? Comments. J Clin Oncol 1990;8:85-90.
25. Kligerman M, Glover D, Turrisi A, et al. Toxicity of WR2721 administered in single and multiple doses. Int J Radiat Oncol Biol Phys 1984;10:1773-6.